The company can now offer its Clinical Exome and Pediatric Neurology Region of Interest diagnostic tests in New York.
The center plans to offer the test for patients with undiagnosed disease and for disease predisposition testing in ostensibly healthy individuals.
Admera's 50-gene PGxOne Plus assay can help predict how patients will respond to drug therapy in cardiology, psychiatry, pain management, and oncology.
The company also reported FY2016 revenues rose 5 percent year over year, despite a dip in product revenues for the year.
The state has given its approval for the company to market its ThyGenX next-generation sequencing oncogene panel for indeterminate thyroid nodules.
The company said it is confident it can address the state health department's concerns and will reapply for approval as soon as possible.
The NGS-based assays will be implemented at Memorial Sloan Kettering Cancer Center alongside targeted DNA sequencing assays to identify gene fusions.
The test, EXaCT-1, may not only help doctors find treatments for patients who have run out of options but may also provide biomarkers of immunotherapy response.
The tests are performed at a CLIA-certified lab, but special licenses from the NY State Department of Health are required to offer the tests in the state.
Following this approval, the firm said it now offers hereditary cancer, cardiology, and pediatric testing services in all 50 US states.
In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.
Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.
HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.
Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.